688
Participants
Start Date
November 29, 2021
Primary Completion Date
August 31, 2026
Study Completion Date
December 31, 2026
Tenecteplase
Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
Standard Care (which may include intravenous Alteplase)
Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Fiona Stanley Hospital, Murdoch
NOT_YET_RECRUITING
Bankstown-Lidcombe Hospital, Bankstown
NOT_YET_RECRUITING
John Hunter Hospital, Newcastle
NOT_YET_RECRUITING
Liverpool Hospital, Sydney
NOT_YET_RECRUITING
Gold Coast Hospital, Gold Coast
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Alfred Health, Melbourne
NOT_YET_RECRUITING
Austin Hospital, Melbourne
RECRUITING
Box Hill Hospital, Melbourne
NOT_YET_RECRUITING
Monash Health, Melbourne
RECRUITING
Royal Melbourne Hospital, Melbourne
NOT_YET_RECRUITING
Western Health, Melbourne
University of Melbourne
OTHER